In a recent British study published in the journal BMJ, the investigators assessed the risks of developing dementia associated with different types and durations of menopausal hormone therapy. The study participants were comprised of 118,501 women aged 55 and older, with a primary diagnosis of dementia between 1998 and 2020.
The control group included 497,416 women. The researchers examined dementia rates within the context of mortality, hormone replacement treatment, demographics, smoking and alcohol consumption, family history and co-morbid history. Overall, no increased risks of developing dementia associated with menopausal hormone therapy were observed. A decreased global risk of dementia was found among cases and controls younger than 80 years who had been taking estrogen-only therapy for 10 years or more.
In conclusion, there does not appear to be a risk of developing dementia and Alzheimer’s disease in women exposed to different types of menopausal hormone therapy, irrespective of treatment duration.
About Women’s Cancer Research Foundation The Women’s Cancer Research Foundation (WCRF) is one of Southern California’s and the nation’s most active research organizations for female cancers. We are dedicated to serving the interests of patients, families, and friends affected by women’s cancers. WCRF partners with physician-scientists nationally to make differences in women’s lives by offering hope, strength, and progress.
361 Hospital Road, Suite 422
Newport Beach, CA 92663
PH: (949) 642-5165
Follow Us On Social Media: